New Optical Treatment Approved

The European medical agency has approved Ozurdex as the EU’s first licensed treatment for macular oedema in patients with retinal vein occlusion.
Manufacturers of the injectable steroid implant with extended drug release, Allergan, claim the implant slowly releases dexamethasone into the vitreous which acts locally to control the oedema and reduce inflammation around the occlusion, improving the patient’s visual acuity.